InMed Pharmaceuticals (INM)

The InMed Pharma pipeline is built around pharmaceutical uses of cannabinoids and related compounds in areas where there remains significant unmet medical need. Its programmes include INM-755, a topical candidate studied for epidermolysis bullosa, a group of rare genetic skin disorders that can cause fragile, blistering skin. The company has also advanced INM-088 for glaucoma and INM-901 for Alzheimer’s disease, reflecting a strategy that looks beyond consumer cannabinoid products and toward regulated therapeutic applications.

BayMedica gives InMed a commercial segment linked to cannabinoid ingredient production. Rare cannabinoids are typically present in low concentrations in the cannabis plant, making scalable and consistent production important for companies seeking to use them in formulations. This business provides InMed with exposure to the broader cannabinoid supply chain while its pharmaceutical candidates remain in development.

As a clinical-stage company, InMed’s investment profile is shaped by research progress, regulatory outcomes, capital needs, and demand for cannabinoid ingredients. Its distinction lies in combining pharmaceutical development with cannabinoid manufacturing capabilities, positioning it at the intersection of biotechnology, specialty ingredients, and cannabinoid research.